Printer Friendly

TECHNICLONE INTERNATIONAL CORP. REPORTS CLINICAL TRIAL UNDER WAY AT BROTMAN MEDICAL CENTER

 TECHNICLONE INTERNATIONAL CORP. REPORTS CLINICAL TRIAL
 UNDER WAY AT BROTMAN MEDICAL CENTER
 TUSTIN, Calif., May 19 /PRNewswire/ -- Techniclone International Corp. reports that a tumor necrosis treatment (TNT-1) clinical trial is under way at the Brotman Medical Center, Culver City, Calif. The clinical trial is directed by Drs. Alan Epstein (U.S. School of Medicine) and Stan Mills (University of Oklahoma Medical Center) and is being performed by Drs. Stephen Strum (oncology) and Laura Thompson (Nuclear Medicine). In collaboration with Patient Advocates for Advanced Cancer Treatment (PAACT), the TNT-1 radioimmunotherapy protocol has been used on four prostate cancer patients. The early results of these first four patients show positive findings and many of the goals of the study have been achieved.
 Of the four patients treated, two patients included in the trials were in the advanced stage of their disease. These two terminal patients were not ideal candidates for this experimental treatment and, regrettably, died of overwhelming disease soon after the treatments were concluded. Ethically, however, these two patients could not be excluded from the trials since they were substantial financial contributors to PAACT and helped bring this trial to the clinic.
 The third and fourth patients continue to be followed by the clinicians and are in the process of receiving additional treatments. One of these patients, who had extensive bony metastases, received three treatments at weekly intervals and has received a second single dose as a second course. He has had excellent uptake in his tumor as shown by nuclear medicine scans and has experienced symptomatic relief of his bone pain and increased mobility of his affected hip and knee joints. The fourth patient, who presented with widely metastatic bony lesions and a soft tissue lung lesion, received one dose and responded soon thereafter, both symptomatically and objectively. His diplopia (double vision) and reduced neck mobility caused by a metastatic lesion in his cervical spine improved dramatically and his PSA, which was 210 at presentation, declined to 4.9 three weeks after therapy. In addition, his lung lesion seen at chest X-ray also showed reduction in size consistent with the improvement seen in the PSA values.
 Based upon these results, the early objectives of the TNT clinical trials have been realized, namely, that TNT can penetrate and bind selectively to metastatic bony and soft tissue lesions in prostate cancer patients. To date, the major toxicity experienced by all the patients was transient pancytopenia (decreased platelet, white cell and red blood cell counts) which can be expected considering the close proximity of the metastatic lesions to normal marrow compartments. These early clinical results indicate that TNT radioimmunotherapy appears quite promising. The treatment of additional patients is planned in the near future once the data from these patients are analyzed. PAACT remains an active supporter of this new technology and has indicated its willingness to assist in the recruitment of patients to appropriate trial sites.
 -0- 5/19/92
 /CONTACT: Lon H. Stone, chairman and CEO of Techniclone International, 714-838-0500/ CO: Techniclone International Corp. ST: California IN: MTC SU:


AL-EH -- LA013 -- 1883 05/19/92 13:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:516
Previous Article:NATIONAL REALTY REPORTS FIRST QUARTER RESULTS
Next Article:FLORIDA PROGRESS DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES FINANCING NEGOTIATIONS
NOVEL ANTI-CANCER DRUG LICENSED TO ALPHA THERAPEUTIC
TECHNICLONE INTERNATIONAL CORP. REPORTS THAT IT HAS RECEIVED A DRUG MANUFACTURING LICENSE FROM CALIFORNIA STATE FOOD AND DRUG
TECHNICLONE INTERNATIONAL CORP. ANNOUNCED TODAY AN AGREEMENT WITH MILLS BIOPHARMACEUTICALS INC.
TECHNICLONE INTERNATIONAL CORP. REPORTS CLINICAL TRIALS ALLOWED BY FDA
TECHNICLONE INTERNATIONAL CORPORATION BEGINS LYM-1 RADIOLABELING MOVES A STEP CLOSER TO TREATMENT FOR NON-HODGKIN'S LYMPHOMA
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES NRC LICENSING OF OKLAHOMA RADIO LABELING FACILITY
TECHNICLONE AND ALPHA THERAPEUTIC ANNOUNCE PATIENT ENROLLMENT IN PHASE III TRIAL OF ONCOLYM(TM) FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA
SuperGen Licenses Angiogenesis Drug-Targeting Technology from Techniclone.
OXiGENE and TECHNICLONE Form Company to Commercialize Products in the Vascular Targeting Area.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters